Terms: = Lung cancer AND STAT3, FLJ20882, 6774, ENSG00000168610, APRF, P40763, MGC16063 AND Treatment
631 results:
1. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
Salembier R; De Haes C; Bellemans J; Demeyere K; Van Den Broeck W; Sanders NN; Van Laere S; Lyons TR; Meyer E; Steenbrugge J
Breast Cancer Res; 2024 Apr; 26(1):63. PubMed ID: 38605414
[TBL] [Abstract] [Full Text] [Related]
2. IL-17 induces NSCLC cell migration and invasion by elevating MMP19 gene transcription and expression through the interaction of p300-dependent stat3-K631 acetylation and its Y705-phosphorylation.
Ge W; Li YA; Ruan Y; Wu N; Ma P; Xu T; Shu Y; Wang Y; Qiu W; Zhao C
Oncol Res; 2024; 32(4):625-641. PubMed ID: 38560562
[TBL] [Abstract] [Full Text] [Related]
3. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell lung cancer Cells by Inhibiting MCL-1 Expression via MET/stat3/Akt Pathway.
Wang L; Xu L; Han S; Zhu X
Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
[TBL] [Abstract] [Full Text] [Related]
4. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
[TBL] [Abstract] [Full Text] [Related]
5. 5-Methoxytryptophan enhances the sensitivity of sorafenib on the inhibition of proliferation and metastasis for lung cancer cells.
Chen HC; Kuo CY; Chang Y; Tsai DL; Lee MH; Lee JY; Lee HM; Su YC
BMC Cancer; 2024 Feb; 24(1):248. PubMed ID: 38388902
[TBL] [Abstract] [Full Text] [Related]
6. A coumarin-furoxan hybrid as novel nitric oxide donor induced cell apoptosis and ferroptosis in NSCLC by promoting S-nitrosylation of stat3 and negative regulation of JAK2-stat3 pathway.
Cao F; Li M; Wang W; Yi Y; Chen Y; Liu H
Biochem Pharmacol; 2024 Apr; 222():116068. PubMed ID: 38387529
[TBL] [Abstract] [Full Text] [Related]
7. MiR-320a upregulation contributes to the effectiveness of pemetrexed by inhibiting the growth and invasion of human lung cancer cell line (Calu-6).
Ghorbani Alvanegh A; Arpanaei A; Esmaeili Gouvarchin Ghaleh H; Mohammad Ganji S
Mol Biol Rep; 2024 Feb; 51(1):310. PubMed ID: 38372812
[TBL] [Abstract] [Full Text] [Related]
8. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B; Pons-Tostivint E; Park K; Hartl S; Forde PM; Hochmair MJ; Awad MM; Thomas M; Goss G; Wheatley-Price P; Shepherd FA; Florescu M; Cheema P; Chu QSC; Kim SW; Morgensztern D; Johnson ML; Cousin S; Kim DW; Moskovitz MT; Vicente D; Aronson B; Hobson R; Ambrose HJ; Khosla S; Reddy A; Russell DL; Keddar MR; Conway JP; Barrett JC; Dean E; Kumar R; Dressman M; Jewsbury PJ; Iyer S; Barry ST; Cosaert J; Heymach JV
Nat Med; 2024 Mar; 30(3):716-729. PubMed ID: 38351187
[TBL] [Abstract] [Full Text] [Related]
9. Tumor cell senescence-induced macrophage CD73 expression is a critical metabolic immune checkpoint in the aging tumor microenvironment.
Deng Y; Chen Q; Yang X; Sun Y; Zhang B; Wei W; Deng S; Meng J; Hu Y; Wang Y; Zhang Z; Wen L; Huang F; Wan C; Yang K
Theranostics; 2024; 14(3):1224-1240. PubMed ID: 38323313
[No Abstract] [Full Text] [Related]
10. Antibody-Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/stat3 Signaling.
Sankar AP; Cho HM; Shin SU; Sneh T; Ramakrishnan S; Elledge C; Zhang Y; Das R; Gil-Henn H; Rosenblatt JD
Cancer Res Commun; 2024 Mar; 4(3):738-756. PubMed ID: 38315147
[TBL] [Abstract] [Full Text] [Related]
11. Network pharmacology study to explore the multiple molecular mechanism of SH003 in the treatment of non-small cell lung cancer.
Lee K; Choi YJ; Lim HI; Cho KJ; Kang N; Ko SG
BMC Complement Med Ther; 2024 Feb; 24(1):70. PubMed ID: 38303001
[TBL] [Abstract] [Full Text] [Related]
12. The Ethanolic Extract of
Park HJ; Park SH
Nutr Cancer; 2024; 76(3):305-315. PubMed ID: 38185896
[No Abstract] [Full Text] [Related]
13. The role of tumor-associated macrophages in lung cancer: From mechanism to small molecule therapy.
Zhou Y; Qian M; Li J; Ruan L; Wang Y; Cai C; Gu S; Zhao X
Biomed Pharmacother; 2024 Jan; 170():116014. PubMed ID: 38134634
[TBL] [Abstract] [Full Text] [Related]
14. Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/stat3/AKT pathway.
Wang J; He X; Jia Z; Yan A; Xiao K; Liu S; Hou M; Long Y; Ding X
Pharm Biol; 2024 Dec; 62(1):33-41. PubMed ID: 38100532
[TBL] [Abstract] [Full Text] [Related]
15. Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells.
Xia L; Liu JY; Yang MY; Zhang XH; Jiang Y; Yin QQ; Luo CH; Liu HC; Kang ZJ; Zhang CT; Gao BB; Zhou AW; Cai HY; Waller EK; Yan JS; Lu Y
Cancer Res; 2024 Feb; 84(3):479-492. PubMed ID: 38095536
[TBL] [Abstract] [Full Text] [Related]
16. CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/stat3 signaling pathway.
Liu YN; Tsai MF; Wu SG; Chang TH; Shih JY
Life Sci; 2024 Jan; 336():122345. PubMed ID: 38092140
[TBL] [Abstract] [Full Text] [Related]
17. KRAS G12C-mutant driven non-small cell lung cancer (NSCLC).
Rosell R; Codony-Servat J; González J; Santarpia M; Jain A; Shivamallu C; Wang Y; Giménez-Capitán A; Molina-Vila MA; Nilsson J; González-Cao M
Crit Rev Oncol Hematol; 2024 Mar; 195():104228. PubMed ID: 38072173
[TBL] [Abstract] [Full Text] [Related]
18. 3,3',5,5'-Tetramethoxybiphenyl-4,4'diol triggers oxidative stress, metabolic changes, and apoptosis-like process by reducing the PI3K/AKT/NF-κB pathway in the NCI-H460 lung cancer cell line.
Concato-Lopes VM; Silva TF; Detoni MB; Cruz EMS; Gonçalves MD; da Silva Bortoleti BT; Tomiotto-Pellissier F; Carloto ACM; Madureira MB; Rodrigues ACJ; Schirmann JG; Barbosa-Dekker AM; Dekker RFH; Conchon-Costa I; Panis C; Lazarin-Bidóia D; Miranda-Sapla MM; Mantovani MS; Pavanelli WR
Biomed Pharmacother; 2024 Jan; 170():115979. PubMed ID: 38061138
[TBL] [Abstract] [Full Text] [Related]
19. Identification of Bulbocodin D and C as novel stat3 inhibitors and their anticancer activities in lung cancer cells.
He X; Fu J; Lyu W; Huang M; Mo J; Cheng Y; Xu Y; Zheng L; Zhang X; Qi L; Zhang L; Zheng Y; Huang M; Ni L; Lu J
Chin J Nat Med; 2023 Nov; 21(11):842-851. PubMed ID: 38035939
[TBL] [Abstract] [Full Text] [Related]
20. Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/stat3 in NSCLC.
Song X; Wang L; Tang W; Yuan L; Liu Q; Li J; Fan D
Arch Pharm Res; 2023 Dec; 46(11-12):924-938. PubMed ID: 38032449
[TBL] [Abstract] [Full Text] [Related]
[Next]
